ROIV - Roivant

-

$undefined

N/A

(N/A)

Roivant NasdaqGS:ROIV Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Location: 50 Broadway, London, SW1H 0DB, United Kingdom | Website: https://roivant.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.395B

Cash

4.887B

Avg Qtr Burn

-209.9M

Short % of Float

13.84%

Insider Ownership

29.44%

Institutional Own.

79.41%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Brepocitinib Details
Dermatomyositis

Phase 3

Data readout

Batoclimab Details
Eye disease , Thyroid Eye Disease

Phase 3

Data readout

Batoclimab Details
Myasthenia gravis

Phase 3

Update

RVT-3101 Details
Ulcerative colitis

Phase 3

Initiation

Brepocitinib Details
Systemic lupus erythematosus, Chronic non-infectious uveitis, Dermatomyositis

Phase 3

Initiation

Mosliciguat Details
Pulmonary hypertension associated with interstitial lung disease

Phase 2

Data readout

RVT-3101 Details
Crohns disease

Phase 2

Data readout

Phase 2

Initiation

RVT-2001 Details
Myelodysplastic syndrome

Failed

Discontinued

Failed

Discontinued